ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) Nov 10, 2025 06:00AM
Form SCHEDULE 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P. Oct 1, 2025 09:19PM
ARS Pharmaceuticals secures $250 million loan facility for neffy expansion Sep 29, 2025 04:06PM
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy® Sep 29, 2025 04:05PM
Form SC 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P. Mar 29, 2024 04:14PM


Sep 25, 2023 04:31PM Form SC 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
Aug 31, 2023 05:26PM Form SC 13D ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
Nov 8, 2022 04:04PM ARS Pharmaceuticals (SPRY) Closes Merger with Silverback Therapeutics (SBTX)
Nov 8, 2022 04:02PM ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
Nov 8, 2022 04:02PM ARS Pharmaceuticals Closes Merger with Silverback Therapeutics